Induction of p53 expression and function by estrogen in osteoblasts.

Area of Science:

• Bone biology
• Endocrinology
• Molecular genetics

Background:

• Estrogen's role in bone health is primarily linked to osteoclasts, with limited understanding of its effects on osteoblasts.
• The p53 tumor suppressor gene's function in osteoblast differentiation is an area of ongoing research.

Purpose of the Study:

• To investigate the role of estrogen (E2) in osteoblast growth and differentiation.
• To determine the effect of estrogen on p53 gene function within osteoblasts.

Main Methods:

• Utilized ROS 17/2.8 cells transfected with a p53 response element-chloramphenicol acetyl transferase (CAT) construct to measure p53 activity.
• Administered varying concentrations of E2 and monitored p53 activity, p53-regulated gene expression (p21, mdm2), and bone-specific markers (osteocalcin, alkaline phosphatase).
• Assessed the impact of estrogen antagonist ICI 182,780 and cycloheximide on E2-induced effects.

Main Results:

• Maximal p53 activity was observed with E2 concentrations between 10(-12) and 10(-15) M, peaking at 16 hours.
• E2 treatment increased p53 activity, leading to elevated expression of p21 and mdm2.
• Bone-specific markers osteocalcin and alkaline phosphatase increased following E2 treatment, with E2 receptor alpha and beta levels also changing.
• Estrogen antagonist partially inhibited the increase in p53 activity, and cycloheximide reduced E2-induced osteocalcin upregulation.

Conclusions:

• Estrogen (E2) can directly increase p53 expression and function in osteoblasts.
• Estrogen plays a significant role in promoting osteoblast growth and differentiation through p53-dependent pathways.
• Findings contribute to understanding the molecular mechanisms underlying estrogen's effects on bone metabolism.